The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
Open accessAbstract
PD-1 is an immunoreceptor that belongs to the immunoglobulin (Ig) superfamily and contains two tyrosine residues in the cytoplasmic region. Studies on PD-1-deficient mice have shown that PD-1 plays critical roles in establishment and/or maintenance of peripheral tolerance, but the mode of action is totally unknown. To study the molecular mechanism for negative regulation of lymphocytes through the PD-1 receptor, we generated chimeric molecules composed of the IgG Fc receptor type IIB (FcγRIIB) extracellular region and the PD-1 cytoplasmic region and expressed them in a B lymphoma cell line, IIA1.6. Coligation of the cytoplasmic region of PD-1 with the B cell receptor (BCR) in IIA1.6 transformants inhibited BCR-mediated growth retardation, Ca 2+ mobilization, and tyrosine phosphorylation of effector molecules, including Igβ, Syk, phospholipase C-γ2 (PLCγ2), and ERK1/2, whereas phosphorylation of Lyn and Dok was not affected. Mutagenesis studies indicated that these inhibitory effects do not require the N-terminal tyrosine in the immunoreceptor tyrosine-based inhibitory motif-like sequence, but do require the other tyrosine residue in the C-terminal tail. This tyrosine was phosphorylated and recruited src homology 2-domain-containing tyrosine phosphatase 2 (SHP-2) on coligation of PD-1 with BCR. These results show that PD-1 can inhibit BCR signaling by recruiting SHP-2 to its phosphotyrosine and dephosphorylating key signal transducers of BCR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Self-citationExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Self-citationFcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Cited by
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
“Two phosphatases, SH2-domain containing tyrosine phosphatase 1 (SHP-1) and SHP-2, can bind to the ITIM and ITSM motifs of PD-1 (35, 36).”
BackgroundMethodWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
“In contrast, inhibitory motif–containing molecules such as PD-1 can recruit phosphatases (such as SHP-1, SHP-2 or SHIP) to TCR-proximal signaling complexes and attenuate signalin”
BackgroundPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
“Although Y224 was reported to be dispensable for the ability of PD1 to co-immunoprecipitate with Shp2 (29, 30), our quantitative, direct binding assay shows that both tyrosines in the PD-1 cytosolic domain contribute to Shp2 binding.”
BackgroundSharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Self-citationMolecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
“As shown previously, SHP2 was recruited to PD-1 upon the PD-1–PD-L1 or –PD-L2 binding, whereas the PD-1–SHP1 association remained at background level (Fig.”
BackgroundInfluentialControl of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Self-citationBTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
“The intracellular tail of PD-1 contains an immunotyrosine inhibitorymotif (ITIM) and an immunotyrosine switchmotif (ITSM), that can recruit phosphatases such as SHP-2, allowing dephosphorylation of key signal transducers (Chemnitz et al., 2004; Okazaki et al., 2001).”
BackgroundSheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
“We and others have shown that PD-1 is quite functional when it contains just a single tyrosine molecule (26, 46).”
BackgroundInfluentialBlank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Self-citationThe PD-1–PD-L pathway in immunological tolerance
Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721
Self-citationRegulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 639
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Self-citationThe PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 535
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 518
Reactive Oxygen Species in the Tumor Microenvironment: An Overview
Weinberg, F., Ramnath, N., & Nagrath, D. (2019) · Cancers · doi:10.3390/cancers11081191 · Cited by 502
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A., & Wherry, E. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142237 · Cited by 467
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
Self-citationRole of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444
“PD-1 transduces an inhibitory signal when it is bound by its ligands in the presence of TCR or BCR activation (5,33,34).”
BackgroundEstablishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505497102 · Cited by 437
Self-citationB lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2018) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 433
PD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405
“PD-1 limits the activity of T cells by inducing a phosphatase that inhibits T-cell receptor downstream signaling (2, 4, 5).”
BackgroundChamoto, K., Chowdhury, P. S., Kumar, A., Sonomura, K., Matsuda, F., Fagarasan, S., & Honjo, T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620433114 · Cited by 413
Self-citationStructural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E. A., Sobel, R. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2871 · Cited by 394
PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, K., Kurata, M., Hayashi, T., et al. (2008) · Blood · doi:10.1182/blood-2007-05-085159 · Cited by 401
Thommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umana, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 395
PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver
Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., & Honjo, T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022235 · Cited by 392
Self-citationAt the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Qin, W., Hu, L., Zhang, X., Jiang, S., Li, J., Zhang, Z., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02298 · Cited by 369
Dendritic cell-mediated T cell polarization
de Jong, E. C., Smits, H. H., & Kapsenberg, M. L. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0167-1 · Cited by 367
Murine B7-H3 is a negative regulator of T cells
Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2500 · Cited by 368
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C., Howard, E. D., Chadwick, E. M., Johnston, J., Hammond, A., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 356
Saeidi, A., Zandi, K., Cheok, Y. Y., Saeidi, H., Wong, W. F., Lee, C. Y. Q., Cheong, H. C., Yong, Y. K., Larsson, M., & Shankar, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02569 · Cited by 350
Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 342
Self-citationProgrammed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis
Lázár-Molnár, E., Chen, B., Sweeney, K. A., Wang, E. J., Liu, W., Lin, J., Porcelli, S. A., Almo, S. C., Nathenson, S. G., & Jacobs, W. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007394107 · Cited by 338
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Park, J.-J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 330
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Burton, A. R., Pallett, L. J., McCoy, L. E., Suveizdyte, K., Amin, O. E., Swadling, L., Alberts, E., Davidson, B. R., Kennedy, P. T. F., Gill, U. S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121960 · Cited by 330
B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis
Mazanet, M. M., & Hughes, C. C. W. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3581 · Cited by 326
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
Balancing co-stimulation and inhibition with BTLA and HVEM
Murphy, K. M., Nelson, C. A., & Šedý, J. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1917 · Cited by 309
Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P., Matsuzaki, J., & Odunsi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 308
Weber, J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.005 · Cited by 306
Role of PD-1 in Regulating T-Cell Immunity
Jin, H.-T., Ahmed, R., & Okazaki, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_116 · Cited by 305
Self-citationStrength of PD-1 signaling differentially affects T-cell effector functions
Wei, F., Zhong, S., Ma, Z., Kong, H., Medvec, A., Ahmed, R., Freeman, G. J., Krogsgaard, M., & Riley, J. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305394110 · Cited by 304
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Zhu, X., & Lang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18311 · Cited by 303
Feske, S. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00818.x · Cited by 299
A snapshot of the PD-1/PD-L1 pathway
Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 292
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
Bennett, F., Luxenberg, D., Ling, V., Wang, I.-M., Marquette, K., Lowe, D., Khan, N., Veldman, G., Jacobs, K. A., Valge-Archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 281
Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., & Honjo, T. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00142-6 · Cited by 280
Self-citationB7-H1 pathway and its role in the evasion of tumor immunity
Dong, H., & Chen, L. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0430-2 · Cited by 276
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 270
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Molecular mechanism of SHP2 activation by PD-1 stimulation
Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., Brandt, H. J., Kirkpatrick, J., Rios, P., Schamel, W. W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4458 · Cited by 262
Chen, S.-W., Zhu, S.-Q., Pei, X., Qiu, B.-Q., Xiong, D., Long, X., Lin, K., Lu, F., Xu, J.-J., & Wu, Y.-B. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01448-x · Cited by 256
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
The dual-function CD150 receptor subfamily: the viral attraction
Sidorenko, S. P., & Clark, E. A. (2003) · Nature Immunology · doi:10.1038/ni0103-19 · Cited by 252
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
“While CD28 is expressed on most mature T cells, CTLA-4 levels are transiently upregulated on mature CD4+ and CD8+ cells during activation (42, 43).”
BackgroundInfluentialNielsen, C., Hansen, D., Husby, S., Jacobsen, B. B., & Lillevang, S. T. (2003) · Tissue Antigens · doi:10.1046/j.1399-0039.2003.00136.x · Cited by 232
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Self-citationInteraction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G. J., & Boussiotis, V. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0845-0 · Cited by 169
Yin–Yang of costimulation: crucial controls of immune tolerance and function
Nurieva, R. I., Liu, X., & Dong, C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00769.x · Cited by 157
Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo
Rota, G., Niogret, C., Dang, A. T., Barros, C. R., Fonta, N. P., Alfei, F., Morgado, L., Zehn, D., Birchmeier, W., Vivier, E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.026 · Cited by 155
Kummer, M. P., Ising, C., Kummer, C., Sarlus, H., Griep, A., Vieira‐Saecker, A., Schwartz, S., Halle, A., Brückner, M., Händler, K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108662 · Cited by 127
“…by the ligands PD-L1 (gene name Cd274) or PD-L2, also type I transmembrane proteins, results in the recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to one of the intracellular motifs, which dephosphorylates and inactivates effector proteins (Okazaki et al , 2001; Chemnitz et al , 2004).”
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87
Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA
Gavrieli, M., & Murphy, K. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.036 · Cited by 85
PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition
Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021) · Nature Communications · doi:10.1038/s41467-021-22965-9 · Cited by 81
PD-1 coinhibitory signals: the link between pathogenesis and protection
Kulpa, D. A., Lawani, M., Cooper, A., Peretz, Y., Ahlers, J., & Sékaly, R.-P. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.02.002 · Cited by 70
Metadata
- Authors
- Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-11-06
- Volume
- 98
- Issue
- 24
- Pages
- 13866-13871
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2086397613
- Cited by
- 848
- References
- 31
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.